127 related articles for article (PubMed ID: 7511190)
21. Correspondence re: Kaiserling E, Horny HP, Geerts M-L, Schmid U: Skin involvement in myelogenous leukemia: morphologic and immunophenotypic heterogeneity of skin infiltrates. Mod Pathol 7:771, 1994.
Orazi A
Mod Pathol; 1995 Apr; 8(3):340-1. PubMed ID: 7542388
[No Abstract] [Full Text] [Related]
22. Phenotypic analysis and characterization of CD34+ cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autologous stem cell transplantation.
Bender JG; Unverzagt K; Walker DE; Lee W; Smith S; Williams S; Van Epps DE
Clin Immunol Immunopathol; 1994 Jan; 70(1):10-8. PubMed ID: 7505211
[TBL] [Abstract][Full Text] [Related]
23. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment.
Orazi A; Cattoretti G; Soligo D; Luksch R; Lambertenghi-Deliliers G
Leukemia; 1993 Jun; 7(6):838-47. PubMed ID: 7684797
[TBL] [Abstract][Full Text] [Related]
24. Evidence for a lymphotropic nature of circulating plasmacytoid monocytes: findings from a case of CD56+ chronic myelomonocytic leukemia.
Horny HP; Kaiserling E; Handgretinger R; Ruck P; Frank D; Weber R; Jaschonek KG; Waller HD
Eur J Haematol; 1995 Apr; 54(4):209-16. PubMed ID: 7540556
[TBL] [Abstract][Full Text] [Related]
25. Further investigations on the expression of HLA-DR, CD33 and CD13 surface antigens in purified bone marrow and peripheral blood CD34+ haematopoietic progenitor cells.
Pierelli L; Teofili L; Menichella G; Rumi C; Paoloni A; Iovino S; Puggioni PL; Leone G; Bizzi B
Br J Haematol; 1993 May; 84(1):24-30. PubMed ID: 7687858
[TBL] [Abstract][Full Text] [Related]
26. Immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications.
Shao Z; Chen G; Lin Z; Zhang Y; Hao Y; Chu Y; Zheng Y; Qian L; Yang T; Yang C; Feng B
Chin Med J (Engl); 1998 Jan; 111(1):28-31. PubMed ID: 10322648
[TBL] [Abstract][Full Text] [Related]
27. Residual normal, highly proliferative progenitors can be isolated from the CD34+/33- fraction of AML with a more differentiated phenotype (CD33+).
Raymakers R; Wittebol S; Pennings A; Linders E; Poddighe P; De Witte T
Leukemia; 1995 Mar; 9(3):450-7. PubMed ID: 7533867
[TBL] [Abstract][Full Text] [Related]
28. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
Papayannidis C; Derenzini E; Iacobucci I; Curti A; Paolini S; Cilloni D; Baccarani M; Martinelli G
Am J Hematol; 2009 Dec; 84(12):849-50. PubMed ID: 19844989
[No Abstract] [Full Text] [Related]
29. Hand mirror variant of adult acute lymphoblastic leukemia. Evidence for a mixed leukemia.
Kovarik P; Shrit MA; Yuen B; Radvany R; Schumacher HR
Am J Clin Pathol; 1992 Nov; 98(5):526-30. PubMed ID: 1283057
[TBL] [Abstract][Full Text] [Related]
30. Acute nonlymphocytic leukemia presenting with pancytopenia.
Hsia CC; Lazo-Langner A
Blood; 2012 Feb; 119(6):1333. PubMed ID: 22423354
[No Abstract] [Full Text] [Related]
31. Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-) and CD33 (-).
Seshi B; Kashyap A; Bennett JM
Br J Haematol; 1992 Jul; 81(3):374-7. PubMed ID: 1382546
[TBL] [Abstract][Full Text] [Related]
32. Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes.
Kitagawa M; Kamiyama R; Kasuga T
Eur J Haematol; 1993 Jul; 51(1):56-8. PubMed ID: 8348949
[No Abstract] [Full Text] [Related]
33. Chronic lymphocytic leukemia coexisting with chronic myelomonocytic leukemia.
Ferrara F; Del Vecchio L; Antonolfi I; Mele G; Rametta V; Cimino R
Haematologica; 1992; 77(2):171-3. PubMed ID: 1398303
[TBL] [Abstract][Full Text] [Related]
34. Results of aggressive chemotherapy for myelodysplastic syndromes.
Dohy H; Kyo T
Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1428-34. PubMed ID: 3247817
[No Abstract] [Full Text] [Related]
35. Chronic myelomonocytic leukemia derived from a possible common progenitor of monocytes and natural killer cells.
Kojima H; Bai A; Mukai HY; Hori M; Komeno T; Hasegawa Y; Ninomiya H; Mori N; Nagasawa T
Leuk Lymphoma; 2000 May; 37(5-6):617-21. PubMed ID: 11042523
[TBL] [Abstract][Full Text] [Related]
36. Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia.
Derolf AR; Björklund E; Mazur J; Björkholm M; Porwit A
Leuk Lymphoma; 2008 Jul; 49(7):1279-91. PubMed ID: 18604716
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
38. Skin involvement in myelogenous leukemia: morphologic and immunophenotypic heterogeneity of skin infiltrates.
Kaiserling E; Horny HP; Geerts ML; Schmid U
Mod Pathol; 1994 Sep; 7(7):771-9. PubMed ID: 7824512
[TBL] [Abstract][Full Text] [Related]
39. New landscapes in the management of myelodysplastic syndromes and chronic myelomonocytic leukemia: oral decitabine.
Niscola P; Mazzone C; Molica M; de Fabritiis P
Future Oncol; 2021 Jun; 17(16):1973-1975. PubMed ID: 33878941
[No Abstract] [Full Text] [Related]
40. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG
Leukemia; 2017 Dec; 31(12):2799-2806. PubMed ID: 28546581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
